Details

Autor(en) / Beteiligte

• Spurney, Christopher F.
• Rocha, Carolina Tesi
• Henricson, Erik
• Florence, Julaine
• Mayhew, Jill
• Gorni, Ksenija
• Pasquali, Livia
• Pestronk, Alan
• Martin, Gerard R.
• Hu, Fengming
• Nie, Lei
• Connolly, Anne M.
• Escolar, Diana M.

Titel

CINRG pilot trial of coenzyme Q10 in steroid-treated duchenne muscular dystrophy

Ist Teil von

• Muscle & nerve, 2011-08, Vol.44 (2), p.174-178

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Introduction: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin‐deficient muscle. Methods: We performed an open‐label, “add‐on” pilot study of CoQ10 in thirteen 5–10‐year‐old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score. Results: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subject‐ and administration‐dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03). Conclusions: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD. Muscle Nerve, 2011